Zhitong Financial APP News, Shanghai Fosun Pharmaceutical (600196.SH) notice, recently, the company's holding subsidiary Shanghai Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Shanghai Fosun Pharmaceutical Industry") received a notice from the State Drug Administration on agreeing to FCN-159 tablets ("the new drug") for histiocytic tumor treatment to carry out clinical trials. Shanghai Fosun Pharmaceutical Industries plans to carry out phase II clinical trials of this indication in China when the conditions are available.
复星医药(600196.SH)：FCN-159片获批开展用于组织细胞肿瘤治疗临床试验
Shanghai Fosun Pharmaceutical (600196.SH): FCN-159 tablets are approved to carry out clinical trials for the treatment of histiocytic tumors
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.